Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03616223 · ClinicalTrials.gov registry record · Phase 1
FX-322 in Sensorineural Hearing Loss
A Phase 1 study, sponsored by Frequency Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT03616223 is a Phase 1 study that has completed, run by Frequency Therapeutics. The registered enrollment target is 23 participants.
The verdict
NCT03616223, a Phase 1 study, has completed, sponsored by Frequency Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
This is a phase 1/2 study of FX-322 at two dose levels compared to placebo in male and female adults otherwise healthy with stable sensorineural hearing loss.
Interventions
- DRUG Placebo
- DRUG FX-322
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2018-07-03 |
| Est. Completion | 2018-12-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03616223
The ClinicalTrials.gov registry entry for NCT03616223 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Frequency Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03616223 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03616223 about?
NCT03616223 is a clinical study titled "FX-322 in Sensorineural Hearing Loss". This is a phase 1/2 study of FX-322 at two dose levels compared to placebo in male and female adults otherwise healthy with stable sensorineural hearing loss.
What is the current status of trial NCT03616223?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2018-07-03. Estimated completion is 2018-12-18.
What interventions are being tested in trial NCT03616223?
The interventions under investigation include: Placebo (DRUG), FX-322 (DRUG).
Who is sponsoring clinical trial NCT03616223?
This trial is sponsored by Frequency Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.